Hospital of the University of Pennsylvania - Medical Intensive Care Unit
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT02207114
The proposed work will provide critical insights into the potential impact of a biomarker-based algorithm on reducing unnecessary antibiotic use in different adult and pediatric/neonatal ICU's. This proposal will also assess the costs (or savings) of a biomarker-based intervention. Overall, the results of this work will be critical in informing future strategies to eliminate unnecessary antibiotic use and curb the continued rise in antimicrobial resistance.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Philadelphia, Pennsylvania, 19104, United States
The goal of this project is reduce unnecessary use of antibiotics in the ICU. The purpose of Phase I of the study is to identify the biomarker, or combination of biomarkers, that provides optimal test characteristics in identifying adults and children/neonates with presumed sepsis who have a very low likelihood of bacterial infection. Results of Phase I will result in development of a biomarker-based algorithm to inform need for antibiotic use in ICU patients. In Phase II, the impact of this biomarker-based algorithm on reducing antibiotic use in the ICU will be determined. Costs or savings associated with the algorithm will also be assessed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
SIRS is considered to be present when patients have more than one of the following clinical findings:
Exclusion criteria
An immunocompromising condition will be defined as one of the following:
These criteria all represent conditions in which antibiotic use is much less likely to be decreased regardless of the results of a biomarker and are consistent with exclusion criteria used in past studies of the impact of biomarkers.
The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
Time frame: Two years
The primary outcome is the duration of antibiotic treatment after enrollment, expressed in days. This variable will focus specifically on the antibiotic agents given for the episode of presumed sepsis for which the patient was included in the study.
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 6 days
This includes assessing ICU mortality, hospital mortality, or hospital discharge as an ultimate outcome.
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 6 days
A secondary outcome of length of stay both in the Intensive Care Unit as well as total hospital stay after enrollment will be assessed.
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 6 days
This secondary outcome measure is defined as resolution of sepsis. Clinical signs and symptoms present at the time of enrollment as well as the presence in any clinical cultures of antimicrobial resistant organisms not present prior to enrollment will be ascertained.
University of Pennsylvania
Other
Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network - Randomized Control Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06539884
Infections, Inflammation
Antalya, Turkey (Türkiye)
View Trial DetailsNCT06181604
Infections, Inflammation
Boston, Massachusetts, United States
View Trial DetailsNCT07072871
Critical Illness, Disease Attributes
Medan, Sumatera, Indonesia
View Trial DetailsNCT00736723
Critical Illness, Critically Ill
Ulm, Germany
View Trial Details